JP2017210484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017210484A5 JP2017210484A5 JP2017162282A JP2017162282A JP2017210484A5 JP 2017210484 A5 JP2017210484 A5 JP 2017210484A5 JP 2017162282 A JP2017162282 A JP 2017162282A JP 2017162282 A JP2017162282 A JP 2017162282A JP 2017210484 A5 JP2017210484 A5 JP 2017210484A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- cooh
- hydrogen
- oso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 6
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461935246P | 2014-02-03 | 2014-02-03 | |
| US61/935,246 | 2014-02-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567477A Division JP6200603B2 (ja) | 2014-02-03 | 2015-02-03 | 化学療法剤としてのβ置換βアミノ酸および類似体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189332A Division JP2019023214A (ja) | 2014-02-03 | 2018-10-04 | 化学療法剤としてのβ置換βアミノ酸および類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017210484A JP2017210484A (ja) | 2017-11-30 |
| JP2017210484A5 true JP2017210484A5 (enExample) | 2018-03-22 |
| JP6417003B2 JP6417003B2 (ja) | 2018-10-31 |
Family
ID=52589758
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567477A Active JP6200603B2 (ja) | 2014-02-03 | 2015-02-03 | 化学療法剤としてのβ置換βアミノ酸および類似体 |
| JP2017162282A Active JP6417003B2 (ja) | 2014-02-03 | 2017-08-25 | 化学療法剤としてのβ置換βアミノ酸および類似体 |
| JP2018189332A Withdrawn JP2019023214A (ja) | 2014-02-03 | 2018-10-04 | 化学療法剤としてのβ置換βアミノ酸および類似体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567477A Active JP6200603B2 (ja) | 2014-02-03 | 2015-02-03 | 化学療法剤としてのβ置換βアミノ酸および類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189332A Withdrawn JP2019023214A (ja) | 2014-02-03 | 2018-10-04 | 化学療法剤としてのβ置換βアミノ酸および類似体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9394237B2 (enExample) |
| EP (1) | EP3102195B1 (enExample) |
| JP (3) | JP6200603B2 (enExample) |
| KR (1) | KR101900584B1 (enExample) |
| CN (1) | CN106163509B (enExample) |
| AU (2) | AU2015210638B2 (enExample) |
| BR (1) | BR112016017997A2 (enExample) |
| CA (1) | CA2938571C (enExample) |
| DK (1) | DK3102195T3 (enExample) |
| ES (1) | ES2896882T3 (enExample) |
| IL (1) | IL247099A0 (enExample) |
| MX (1) | MX2016010095A (enExample) |
| NZ (1) | NZ723940A (enExample) |
| SG (2) | SG10201710436WA (enExample) |
| TW (1) | TWI597260B (enExample) |
| WO (1) | WO2015117147A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ723940A (en) * | 2014-02-03 | 2017-12-22 | Quadriga Biosciences Inc | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| US9394236B2 (en) | 2014-02-03 | 2016-07-19 | Quadriga Biosciences, Inc. | β-substituted γ-amino acids and analogs as chemotherapeutic agents |
| US20160346240A1 (en) * | 2014-02-03 | 2016-12-01 | Quadriga Biosciences, Inc. | Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs |
| KR20180035894A (ko) * | 2015-08-03 | 2018-04-06 | 콰드리가 바이오사이언시스 인코포레이티드 | 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도 |
| CN109174181B (zh) * | 2018-08-10 | 2021-05-25 | 华东师范大学 | 一种负载双功能离子液体介孔聚合物的制备及其应用 |
| TW202140440A (zh) * | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2022147743A1 (en) * | 2021-01-08 | 2022-07-14 | Quadriga Biosciences, Inc. | Pharmaceutical compositions of chemotherapeutic agents based on beta-substituted beta-amino acid derivatives |
| EP4320127A1 (en) | 2021-04-05 | 2024-02-14 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| US12427124B1 (en) | 2024-04-10 | 2025-09-30 | Maxymune Therapeutics, Inc. | Phenylalanine-based LAT1 inhibitors and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3235594A (en) | 1962-04-02 | 1966-02-15 | Frosst & Co Charles E | N-acyl-alpha-amino acid amides |
| US3299104A (en) | 1963-04-09 | 1967-01-17 | Leo Ab | Certain steroid nu-bis-(haloethyl)-carbamates |
| DK287977A (da) | 1976-07-12 | 1978-01-13 | Merck & Co Inc | Fremgangsmade til fremstilling af 2-(3-(2-(thiazolyl-eller thiazolinyl)thio) phenyl)-alkan-(eller alken) syrer |
| US4339443A (en) | 1978-09-22 | 1982-07-13 | Fbc Limited | Compounds and compositions |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US5015644A (en) | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| FR2688499B1 (fr) * | 1992-03-10 | 1994-05-06 | Rhone Poulenc Rorer Sa | Procede de preparation de la beta-phenylisoserine et de ses analogues. |
| US5602278A (en) | 1994-10-20 | 1997-02-11 | Kirkpatrick; Lynn | N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells |
| FI972492A0 (fi) | 1994-12-13 | 1997-06-12 | Hoffmann La Roche | Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina |
| TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| JP3163391B2 (ja) * | 1995-03-07 | 2001-05-08 | 味の素株式会社 | スチルベン誘導体及びそれを含有する制癌剤 |
| US6172057B1 (en) | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| EP1475371A1 (en) | 1997-12-16 | 2004-11-10 | Warner-Lambert Company LLC | 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| TWI244481B (en) | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| GB0103857D0 (en) | 2001-02-16 | 2001-04-04 | Avecia Ltd | Preparation of chloromandelic acid |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| WO2003018565A1 (en) | 2001-08-29 | 2003-03-06 | Chirologix Pharmaceuticals Inc. | Method for synthesizing oxazinones |
| US20040087556A1 (en) | 2002-11-06 | 2004-05-06 | Lynn Kirkpatrick | N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor |
| JP2004175692A (ja) | 2002-11-25 | 2004-06-24 | Fuso Pharmaceutical Industries Ltd | 抗腫瘍剤 |
| EP2172197A1 (en) | 2002-12-13 | 2010-04-07 | Warner-Lambert Company LLC | Octanoic acid derivative to treat fibromyalgia and other pains |
| KR101140559B1 (ko) | 2003-08-20 | 2012-07-05 | 제노포트 인코포레이티드 | 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법 |
| WO2005044780A1 (ja) * | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| DK1716115T3 (da) | 2003-12-30 | 2013-05-27 | Xenoport Inc | Syntese af acyloxyalkylcarbamat-prodrug og mellemprodukter deraf |
| EP1745033A4 (en) | 2004-05-08 | 2009-08-26 | Neurogen Corp | 2-ARYLPYRIMIDINES DISUBSTITUTED IN 4,5 |
| US20060223866A1 (en) | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| WO2006036670A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| JP2008540568A (ja) * | 2005-05-12 | 2008-11-20 | アテヌオン・リミテッド・ライアビリティ・カンパニー | 抗血管形成化合物を用いた炎症性腸疾患の治療 |
| JP2008540560A (ja) * | 2005-05-12 | 2008-11-20 | アリゾナ・ボード・オブ・リージェンツ・ア・ボディ・コーポレート・オブ・ザ・ステート・オブ・アリゾナ・アクティング・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステート・ユニバーシティ | スチルベン誘導体並びにがん細胞増殖及び微生物増殖の阻害方法 |
| JP5321061B2 (ja) | 2005-08-11 | 2013-10-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 不飽和複素環誘導体 |
| JP2009504614A (ja) | 2005-08-11 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー病の治療用化合物 |
| TWI328730B (en) | 2006-06-16 | 2010-08-11 | Ablerex Electronics Co Ltd | Maximum power point tracking method and tracker thereof for a solar power system |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| US20080045534A1 (en) | 2006-08-18 | 2008-02-21 | Valeant Pharmaceuticals North America | Derivatives of 1,3-diamino benzene as potassium channel modulators |
| EP1900729A1 (en) | 2006-09-15 | 2008-03-19 | Novartis AG | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
| WO2008088690A2 (en) | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | A process for preparing diazabicyclo[3.3.1] nonane compounds |
| GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
| US20090069419A1 (en) | 2007-09-07 | 2009-03-12 | Bernd Jandeleit | Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| TWI468375B (zh) | 2008-10-27 | 2015-01-11 | Janssen Pharmaceutica Nv | 製備經保護之ｌ－丙胺酸衍生物之方法 |
| HUE025527T2 (en) | 2009-01-19 | 2016-04-28 | Abbvie Inc | Apoptosis inducers for the treatment of cancer, immune and autoimmune diseases |
| CA2758245A1 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
| CN102030683B (zh) | 2009-09-27 | 2013-07-31 | 浙江九洲药业股份有限公司 | 西他列汀中间体及其制备方法和用途 |
| CN103228622B (zh) | 2010-07-23 | 2016-01-20 | 康内克斯生命科学私人有限公司 | Gpr40的激动剂 |
| KR20230038593A (ko) | 2011-09-02 | 2023-03-20 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| KR101352635B1 (ko) | 2011-12-29 | 2014-01-20 | 연세대학교 산학협력단 | 신규 혈관누출 차단제 |
| EP2746250B1 (en) | 2012-12-21 | 2017-09-27 | ABX Advanced Biochemical Compounds GmbH | Precursors and process for the production of 18F-labelled amino acids |
| US20140199728A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| NZ723940A (en) | 2014-02-03 | 2017-12-22 | Quadriga Biosciences Inc | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| KR20180035894A (ko) * | 2015-08-03 | 2018-04-06 | 콰드리가 바이오사이언시스 인코포레이티드 | 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도 |
-
2015
- 2015-02-03 NZ NZ723940A patent/NZ723940A/en not_active IP Right Cessation
- 2015-02-03 CA CA2938571A patent/CA2938571C/en active Active
- 2015-02-03 BR BR112016017997A patent/BR112016017997A2/pt not_active Application Discontinuation
- 2015-02-03 EP EP15706571.5A patent/EP3102195B1/en active Active
- 2015-02-03 ES ES15706571T patent/ES2896882T3/es active Active
- 2015-02-03 SG SG10201710436WA patent/SG10201710436WA/en unknown
- 2015-02-03 MX MX2016010095A patent/MX2016010095A/es unknown
- 2015-02-03 WO PCT/US2015/014303 patent/WO2015117147A1/en not_active Ceased
- 2015-02-03 US US14/613,143 patent/US9394237B2/en active Active
- 2015-02-03 KR KR1020167024186A patent/KR101900584B1/ko active Active
- 2015-02-03 DK DK15706571.5T patent/DK3102195T3/da active
- 2015-02-03 CN CN201580018969.4A patent/CN106163509B/zh active Active
- 2015-02-03 SG SG11201606351VA patent/SG11201606351VA/en unknown
- 2015-02-03 JP JP2016567477A patent/JP6200603B2/ja active Active
- 2015-02-03 AU AU2015210638A patent/AU2015210638B2/en active Active
- 2015-07-30 TW TW104124735A patent/TWI597260B/zh active
-
2016
- 2016-03-07 US US15/063,171 patent/US10034847B2/en active Active
- 2016-06-14 US US15/181,817 patent/US20160296484A1/en not_active Abandoned
- 2016-06-15 US US15/182,851 patent/US9861599B2/en active Active
- 2016-08-03 IL IL247099A patent/IL247099A0/en unknown
-
2017
- 2017-08-25 JP JP2017162282A patent/JP6417003B2/ja active Active
- 2017-10-24 AU AU2017251704A patent/AU2017251704B2/en active Active
- 2017-11-29 US US15/826,042 patent/US10245246B2/en active Active
-
2018
- 2018-10-04 JP JP2018189332A patent/JP2019023214A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017210484A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2006143746A5 (enExample) | ||
| JP2013079282A5 (enExample) | ||
| JP2018529687A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| JP2009543795A5 (enExample) | ||
| JP2010526146A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2013515752A5 (enExample) | ||
| JP2010534246A5 (enExample) | ||
| CU23967B1 (es) | Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial | |
| JP2011525192A5 (enExample) | ||
| JP2018534286A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2008545700A5 (enExample) | ||
| JP2008500999A5 (enExample) | ||
| JP2016514699A5 (enExample) | ||
| JP2009502829A5 (enExample) | ||
| JP2010508335A5 (enExample) | ||
| JP2010520851A5 (enExample) | ||
| JP2019519593A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2010505865A5 (enExample) | ||
| JP2008546770A5 (enExample) |